Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

Stopped early · Phase 1

Conditions studied: Renal Impairment

In brief

The purpose of the study is to determine the pharmacokinetics and safety of elinogrel and its metabolite in patients with mild, moderate, and severe renal impairment compared to healthy volunteers.

Key facts

Study ID

NCT00984113

Run by

Portola Pharmaceuticals

People needed

44

Starts

2009-09-01

Expected to finish

2009-12-01

Last updated by the study team

2023-08-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Able to understand and sign the written informed consent
• Subjects should have either normal renal function or have stable renal disease

You may not qualify if…

• History of heart disease
• Unstable or clinically significant other disorders such as respiratory, hepatic, metabolic, psychiatric or gastrointestinal disorder

Where it is running

• DaVita Clinical Research — Minneapolis, Minnesota, United States
• NOCR-Knoxville — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.